Holen Sie sich die Stockscreener-App
12.92
1.00%
-0.13
Vorhandelsmarkt:
12.91
-0.010
-0.08%
Schlusskurs vom Vortag:
$13.05
Offen:
$13.02
24-Stunden-Volumen:
1.40M
Relative Volume:
0.84
Marktkapitalisierung:
$40.96B
Einnahmen:
$30.27B
Nettoeinkommen (Verlust:
$1.93B
KGV:
21.38
EPS:
0.6044
Netto-Cashflow:
$3.45B
1W Leistung:
-0.23%
1M Leistung:
-3.29%
6M Leistung:
-5.69%
1J Leistung:
-13.06%
1-Tages-Spanne:
$12.92
$13.04
1-Wochen-Bereich:
$12.86
$13.20
52-Wochen-Spanne:
$12.57
$15.08
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Vergleichen Sie TAK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Eingeleitet | Cowen | Market Perform |
| 2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register
Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN
Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia
Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa
Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily
JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily
BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily
What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register
Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):